As of June 9, 2025, Peak Pharmaceuticals Inc (PKPH) reports a ROE (Return on Equity) of 33.59%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Peak Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Peak Pharmaceuticals Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-09-30 | 33.59% |
| 2021-09-30 | 23.33% |
| 2020-09-30 | 6.00% |
| 2019-09-30 | 5.95% |
| 2018-09-30 | 12.85% |
This slight upward trend highlights how Peak Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Peak Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Peak Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Peak Pharmaceuticals Inc (PKPH) | 33.59% |
| Multicell Technologies Inc (MCET) | 263.43% |
| Rasna Therapeutics Inc (RASP) | 227.13% |
| Biosyntech Inc (BSYI) | 194.35% |
| Immune Therapeutics Inc (IMUN) | 140.69% |
| CardioGenics Holdings Inc (CGNH) | 122.61% |
Compared to its competitors, Peak Pharmaceuticals Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.